SP 20104Alternative Names: SP20104
Latest Information Update: 07 Dec 2015
At a glance
- Originator Sarfez Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Nephrotic syndrome
Most Recent Events
- 07 Dec 2015 Phase-II clinical trials in Nephrotic syndrome in USA (unspecified route) prior to December 2015